Navigation Links
Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
Date:6/10/2008

MONTREAL, June 10 /PRNewswire/ - Aegera Therapeutics Inc. is extremely pleased to announce the initiation of a Phase 1 clinical trial of the IAP ("Inhibitor of Apoptosis Protein") inhibitor, HGS1029 (formerly AEG40826), as a monotherapy in patients with advanced solid tumors. This small molecule IAP inhibitor was developed by Aegera and licensed to Human Genome Sciences, Inc. (Nasdaq: HGSI) for oncology development in December 2007. As part of this agreement, Aegera maintains full ownership of all rights to this class of molecules for the Japanese market and global rights for non-oncology indications.

"We are impressed with the research and development teams that HGS has applied to the advancement of this exciting collaborative oncology program. In a very short period of time, their clinical team has advanced this program to its first clinical trial and we are confident that their pro-active approach will lead to the rapid and successful development of this potent molecule across a broad range of cancer indications. In addition, our respective research teams are working very closely together to continue to build on Aegera's IAP expertise and to identify additional back-up and best-in-class compounds to follow the initial lead." commented Dr. Mike Berendt, Aegera President & CEO.

Aegera also announced today the receipt of its first milestone payment under this collaboration agreement. The payment, in the amount of US$5 million, was triggered by the FDA clearance of the Investigational New Drug (IND) application for HGS1029.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs. In additi
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aegera Therapeutics welcomes two experienced executives to its board of directors
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
5. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
6. Loic Maurel Joins Exonhit Therapeutics to Become CEO
7. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
8. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
11. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Look inside the new Preferred Solutions® ... lab, from fluid handling to instruments to supplies. Many ... you order. , Preferred Solutions features a full ... L/S® model for precise flow control and dispensing to ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... young company with a preventive solution to identity theft took ... Burrill Technology Business Plan Competition, but if area investors want ... act quickly. , , Din and Newport stand in ... Khaja M. Din, president IPIC (Internet Privacy & ...
... of capturing 10 percent of the stem cell technology market ... directing the Department of Commerce to spend at least $5 ... companies to Wisconsin. , ,Doyle said the executive order, signed ... to stem cell research. Proponents of stem cell research cite ...
... and services to the financial and health-benefits industries, said ... to $1.1 billion. , ,Net income was $116 million, ... in the first quarter of 2005 on $973 million ... included repurchasing 5.4 million shares of common stock and ...
Cached Biology Technology:Winner of Burrill competition courted by North Carolina investors 2Winner of Burrill competition courted by North Carolina investors 3Doyle authorizes $5 million to woo stem cell companies 2
(Date:7/9/2014)... high levels of vitamin D in their blood are more ... Patients with the highest levels of vitamin D have half ... levels, the findings reveal. , The study is the first ... cancer patients after their diagnosis which includes that produced ... with their long term survival prospects. , The ...
(Date:7/9/2014)... data can yield big savings, if they are ... Bates of the Brigham and Women,s Hospital and ... for cost savingshigh-cost patients; readmissions; triage; decompensation (when ... optimization when a disease affects multiple organ systems. ... though the current costs associated with all six ...
(Date:7/8/2014)... increased risk of severe perineal tearing during childbirth in women ... a new study published today (9 July) in BJOG: ... This study, investigates among women who have had a third ... subsequent pregnancies and the recurrence of severe perineal tears. ... in some women the tear may be more extensive. A ...
Breaking Biology News(10 mins):The impact of big data on health care: Health Affairs' July issue 2Mode of delivery following a perineal tear and recurrence rate in subsequent pregnancies 2
... Mich.---Researchers have developed what they believe is the first new ... used to treat all HIV patients, which could eventually lead ... the University of Michigan used computer models to develop the ... compound does indeed inhibit HIV protease, which is an established ...
... Oregon white oak were once widespread in the Pacific ... Fire suppression, conifer and invasive plant encroachment, and land ... much as 99 percent of the oak communities historically ... new technical report titled "Evaluation of Landscape Alternatives for ...
... experts on evolution will gather in Minnesota June 20 ... gathering of evolutionary biologists. The conference, the premier international ... is sponsored by the University of Minnesota,s Bell Museum ... and Minnesota Citizens for Science Education. Headlining the ...
Cached Biology News:Compound has potential for new class of AIDS drugs 2University of Minnesota to host world's largest conference on evolution 2
... numbers of samples may be carried out using ... minimum operator attention. System control and data ... CE 4900. The elegant, powerful and very ... and Windows 98 and 2000., The supplied automatic ...
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications)....
Biology Products: